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The predominant motor neuron disease in infants and adults is spinal muscular atrophy (SMA) and 
amyotrophic lateral sclerosis (ALS), respectively. SMA is caused by insufficient levels of the Survival 
Motor Neuron (SMN) protein, which operates as part of the multiprotein SMN complex that includes the 
DEAD-box RNA helicase Gemin3/DDX20/DP103. C9orf72, SOD1, TDP-43 and FUS are ranked as the four 
major genes causing familial ALS. Accumulating evidence has revealed a surprising molecular overlap 
between SMA and ALS. Here, we ask the question of whether Drosophila can also be exploited to study 
shared pathogenic pathways. Focusing on motor behaviour, muscle mass and survival, we show that 
disruption of either TBPH/TDP-43 or Caz/FUS enhance defects associated with Gemin3 loss-of-function. 
Gemin3-associated neuromuscular junction overgrowth was however suppressed. Sod1 depletion had 
a modifying effect in late adulthood. We also show that Gemin3 self-interacts and Gem3ΔN, a helicase 
domain deletion mutant, retains the ability to interact with its wild-type counterpart. Importantly, 
mutant:wild-type dimers are favoured more than wild-type:wild-type dimers. In addition to reinforcing 
the link between SMA and ALS, further exploration of mechanistic overlaps is now possible in a 
genetically tractable model organism. Notably, Gemin3 can be elevated to a candidate for modifying 
motor neuron degeneration.
Motor neuron disease (MND) encompasses a seemingly heterogeneous group of neurological conditions that are 
nonetheless characterised by muscle weakness and paralysis thought to arise from the selective degeneration of 
motor neurons. Genetic factors play a major role in disease pathogenesis and the knowledge that mutations in 
genes encoding RNA-binding proteins (RBPs) can lead to MND, underscores RNA dysregulation as a key con-
tributor to motor dysfunction1–4. In infants, the predominant MND is spinal muscular atrophy (SMA), typically 
an autosomal recessive condition caused by inactivating mutations in the survival motor neuron 1 (SMN1) gene 
that are partly counteracted by the paralogous SMN2 gene. Rather than total loss of the SMN1- or SMN2-encoded 
SMN protein, SMA is the result of insufficient SMN levels5. SMN, operating as part of a large multiprotein com-
plex that includes Gemins 2–8 and Unrip, is indispensable for chaperoning the assembly of spliceosomal small 
nuclear ribonucleoproteins (snRNPs)6,7, in addition to a possible role in the assembly and axonal trafficking of 
messenger ribonucleoproteins (mRNPs) in motor neurons8. In adults, the most common MND is amyotrophic 
lateral sclerosis (ALS), which can be inherited (~10%) but is mostly sporadic (~90%). Chromosome 9 open reading 
frame 72 (C9orf72), Cu/Zn superoxide dismutase 1 (SOD1), transactive response DNA binding protein (TARDBP) 
and fused in sarcoma (FUS), in that order, are ranked as the four most common genes causing familial ALS and 
mutations in these genes are increasingly detected in sporadic cases9,10. TAR DNA binding-protein 43 or TDP-43 
(encoded by TARDBP), and FUS are RBPs that are involved in multiple levels of RNA processing11,12.
Although SMA and ALS are traditionally considered as separate MNDs, a notion supported by differences in 
genetic aetiology, disease onset and type of affected motor neurons, accumulating evidence has revealed a surpris-
ing overlap at a molecular level. First, SMN and/or SMN complex members are components of the interactomes 
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of SOD113, TDP-4314,15, FUS16–19 or the dipeptide repeat (DPR) proteins resulting from hexanucleotide repeat 
expansion in the C9orf72 gene20. In addition, both TDP-43 and FUS were reported to localise to gems14,15, which 
are nuclear bodies enriched in SMN complexes7,21,22. Second, both diseases are characterised by disrupted RNA 
processing including snRNP perturbation6,15,18,23–27 and axonal transport defects8,17,28–30. Third, both ALS and 
SMA were found to co-occur within families31. Fourth, an abnormal change in SMN1 copy number including 
gene deletion or duplication increases susceptibility to sporadic ALS32–34, presumably because deviations from 
normal SMN protein levels render motor neurons more vulnerable to degeneration. In corroboration, SMN defi-
ciency was found to accelerate phenotypic severity in mutant SOD1 mice13. Fifth, and most important, a depleted 
number of gems resulting from SMN reduction was identified as a signature feature of ALS in addition to SMA35. 
A follow-up study unexpectedly showed that motor neurons derived from SMA or ALS patients have heteroge-
neous SMN levels with those having low levels being highly susceptible to cell death36. This observation explains 
why increasing SMN levels was found to be beneficial not only to SMA37,38 but also to ALS, at least, in SOD139,40 
and TDP-4341 mouse models. Whether SMA therapeutics elevating SMN levels are also effective in ALS patients 
still remains to be determined.
Known and unknown components of molecular pathways can be uncovered in an unbiased fashion via 
genetic approaches. Drosophila has emerged as a premier model system for this task in view of its genetic tracta-
bility42,43. Indeed, genome-wide screens in Drosophila have yielded several modifier genes that are relevant to the 
pathology underlying either SMA44–47 or ALS48–52. However, the overlap has been surprisingly minimal and one 
study even reported that overexpression or RNAi-mediated knockdown of SMN failed to modify human FUS 
(hFUS)-induced neurodegeneration in Drosophila eyes23. This is in contrast to earlier findings in a cell-based 
system showing that overexpression of SMN rescued axonal defects induced by mutant FUS17. Although a com-
mon pathway uniting SMA and ALS could have developed later in evolution, it is highly likely that the screenable 
phenotype used in Drosophila-based investigations was not adequate to uncover interactions between SMA- and 
ALS-linked proteins. Therefore, the question of whether Drosophila can be exploited to study the shared patho-
genic pathway linking SMA and ALS remains. Here, we address this question by using a different approach. First, 
instead of SMN, we focus on Gemin3, which is a core member of the SMN complex7. Our rationale is based on 
accumulating evidence that has essentially shifted the limelight from SMN to its Gemin associates revealing, a 
previously undisclosed, starring role in the operations of the SMN complex6,53. Second, we probe for a modify-
ing effect in muscle, a tissue that is increasingly considered as a primary site of pathogenesis in both SMA and 
ALS54–59.
Gemin3, also known as DDX20 or DP103, is a DEAD-box RNA helicase which is involved in multiple cellular 
processes60. Most documented are its roles in RNA metabolism, including snRNP biogenesis where it functions 
within the SMN complex. To this end, we have recently shown that, in Drosophila, Gemin3 interacts both genet-
ically and physically with pICln and Tgs1, two fundamental players in the snRNP biogenesis cycle61. Here, we 
extend the functional relationship to three key proteins linked to ALS. Hence, we demonstrate that a combination 
of Gemin3 and TDP-43 or FUS disruption exacerbates viability defects, motor dysfunction and muscle atrophy 
whilst suppressing neuromuscular junction (NMJ) overgrowth. Loss of Sod1 function is also responsible for 
inducing a prominent motoric decline in Gemin3 mutant flies at a late stage in adult life. The likely explanation is 
an interference in a common pathway. Additionally, we show that Gemin3 is capable of self-binding and Gem3ΔN, 
a helicase domain deletion mutant, enhances the association when bound to wild-type Gemin3, an observation 
that offers an explanation for its dominant-negative mechanism of action. Collectively, our data reinforce the link 
between SMA and ALS in addition to giving impetus to further studies on the shared mechanisms in a genetically 
tractable model organism.
Results
overexpression of human TDP-43 in a Gem3 mutant background induces adult lethality. 
Similar to SMN45,62,63, loss of Gemin3 impacts adult viability and induces motor dysfunction64–66. In addition 
to Gemin3, a select number of SMN complex components, including Gemin2, Gemin4, Gemin5, Gemin8 and 
Unrip, are required for neuromuscular function and survival in Drosophila61,64,67. It is therefore highly plau-
sible that SMA is triggered by any perturbation in the stoichiometry of the SMN complex. We have recently 
isolated Gem3BART, a hypomorphic version of the Gem3ΔN mutant, which lacks the N-terminal helicase core. 
Subsequently, we reported that alterations in the levels of SMN complex components precipitate the viability and 
motor phenotypes of Gem3BART adult flies68. A similar outcome was observed on disruption of snRNP biogene-
sis factors pICln and Tgs161. We wished to investigate whether a functional interaction also extends to Gemin3 
and ALS-linked TDP-43. Missense mutations in this protein have been identified in 5% of familial and <1% 
of sporadic ALS cases10. TDP-43, an evolutionarily conserved protein, comprises of 2 RNA recognition motifs 
(RRMs), a nuclear localisation signal and a nuclear export sequence that mediate nuclear shuttling, as well as a 
C-terminal glycine-rich region where the majority of ALS-associated mutations occur11. Importantly, truncated 
TDP-43 is mislocalised from its predominantly nuclear location to ubiquitin-containing cytoplasmic inclusions 
in neurons of both sporadic and most familial forms of ALS10,69,70. Loss of TDP-43 nuclear function has been 
proposed as a primary mechanism linking TDP-43 proteinopathy to neuromuscular degeneration in ALS. In 
this context, we first asked whether decreased levels of TDP-43 can modify Gem3BART phenotypes. We note that 
neither haploinsufficiency (TBPHΔ23) nor RNAi-induced knockdown (TBPH-RNAi) of TBPH, the Drosophila 
TDP-43 homologue, had any effect on motor and viability phenotypes in flies with muscle-restricted Gem3BART 
expression (Fig. 1, Table 1 and data not shown).
Recently, considerable attention has been given to the toxic effect of cytoplasmic TDP-43 protein aggregates71. 
To this end, we next queried whether gain rather than loss of TDP-43 function is a modifying factor. Expression 
of wild-type human TDP-43 (hTDP-43WT) in muscle leads to adult flies that have climbing defects and are entirely 
flightless when compared to controls (Fig. 1). Flies also have a shortened life-span, therefore surviving less than a 
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week post-eclosion. Notably, in combination with Gem3BART, hTDP-43 induced adult lethality with flies dying at 
the pupal stage. Furthermore, transgenes with higher expression levels and/or epitope-tagged versions of hTDP-
43 (hTDP-43WT.GFP#10, weak expression; hTDP-43WT.GFP#16, strong expression; ref. 72) were found to induce 
death at the earlier third instar stage (L3) when combined with Gem3BART in contrast to death at pupal stage when 
they were expressed alone (Table 1). This trend, which was also observed with an independently-generated line 
(Flag.hTDP-43WT, ref. 73; Table 1), shows that phenotypic enhancement is dependent on dose or modifications 
that interfere with protein structure. Muscle-directed expression of hTDP-43CTF, which mimics the major TDP-43 
C-terminal fragment found in cytosolic aggregates of ALS patients, was found to induce lethality at the first instar 
larval stage most likely because the transgene is highly expressing72. This excluded its use for interaction analysis 
(Table 1). Importantly, overexpression of endogenous TBPH replicated the modifier effect of its human counter-
part. Hence, whereas alone it induces death at the pupal stage, when combined with Gem3BART it enhanced sur-
vival defects with flies dying earlier than the L3 stage (Table 1). Overall, these findings are suggestive of a genetic 
interaction between Gemin3 and TBPH or its human homologue, TDP-43.
Knockdown or overexpression of caz/FUS enhances Gem3 mutant phenotypes. FUS is another 
major RBP that is mutated in both familial (5%) and sporadic (<1%) ALS cases10. FUS is a highly-conserved 
protein possessing an N-terminal domain rich in glutamine, glycine, serine and tyrosine residues (QGSY region), 
a glycine-rich region, an RRM, multiple arginine/glycine/glycine (RGG) repeats in an arginine- and glycine-rich 
region, and a zinc finger motif at the C-terminus. Mutations cluster in the glycine-rich region and in the extreme 
C-terminus where the nuclear localisation signal is likely to reside11. Similar to TDP-43, mutant FUS is mislo-
calised to the cytoplasm where it forms ubiquitinated aggregates74. Considering that FUS and TDP-43 function 
Figure 1. Gain-of-function identifies TDP-43 as a modifier of survival in Gem3BART-expressing flies. (A) Left: 
Flight performance was assessed by the Droso-Drome apparatus, where determination of flight capacity is 
based on which sector flies land after they are introduced at the top. Right: Removal of one copy (+/TBPHΔ23) 
or RNAi-mediated knockdown (TBPH-RNAi [Trinity]) of TBPH does not impair the motoric ability of flies 
with pan-muscular expression of Gem3BART. Indeed, at all time points, no significant differences were observed 
between the two groups in the number of flies that had no flight ability (sector 1) compared to those that 
retained the ability to fly (sectors 2–4). In contrast, ectopic expression of wild-type human TDP-43 (hTDP-
43WT) in muscle impairs flight as early as day 5 post-eclosion. Flies were non-fliers, hence they all fell in sector 
1. (B) Climbing success rate of flies with muscle-specific hTDP-43 overexpression was drastically reduced 
compared to control animals. Furthermore, assessment of the time taken for the first fly to reach a pre-set 
threshold determined that flies took significantly longer to attain this goal in contrast to the control genotype. 
In (A,B), data presented are the mean ± S.E.M. of at least 4 independent experiments, and for each time point 
measured, n ≥ 60 per genotype. Symbols indicate the sex of the genotype assessed: ♂ = males, ♀ = females, and 
♀♂ = males + females. Significance as tested by two-way ANOVA, followed by Bonferroni’s post hoc tests (A) 
and the unpaired t-test (B) is indicated by the exact p-value.
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in a common pathway with FUS acting downstream of TDP-4375,76, we hypothesised that Gemin3 is likely 
to have a functional relationship not only with TBPH/TDP-43 but also with FUS. To this end, we first tested 
whether haploinsufficiency of cabeza (caz), the Drosophila homologue of FUS, can induce motor deficits when 
placed in a Gem3BART genetic background. Interestingly, we find a subtle yet statistically significant difference 
in motoric abilities at late adulthood (day 35 post-eclosion) in caz mutant heterozygous flies (caz1/+) that had 
muscle-restricted Gem3BART expression compared to those that did not (Fig. 2). Subsequently, we asked whether 
phenotypic enhancement is dose-dependent. Hence, we induced muscle-specific RNAi-mediated knockdown of 
caz in wild-type versus Gem3BART flies. We observed that a moderately-expressing RNAi transgene targeting the 
C-terminus (caz-RNAi [Kellogg], Supplementary Fig. S1) induced flight defects as early as day 15 post-eclosion 
with flies then exhibiting an age-dependent progressive worsening in phenotype (Fig. 2). A stronger RNAi trans-
gene targeting the same region but based on short hairpin microRNA (shRNA) technology (caz-RNAi [Oriel], 
Supplementary Fig. S1) was capable of inducing motor defects at an earlier stage during adulthood (Fig. 2), fur-
ther confirming that modification is dependent on Caz protein levels with a severe reduction inducing the highest 
impact.
Similar to TDP-43, in addition to loss of nuclear function, a toxic gain of function due to the formation 
of cytoplasmic aggregates has been implicated as a predominant mechanism underpinning FUS-associated 
ALS GENE ALLELE REF.
VIABILITY
Mef2-GAL4> Mef2-GAL4 > + Gem3BART
Hs: TDP-43; Dm: TBPH
LOF: +/TBPHΔ23 73 Adult Viable Adult Viable
LOF1: TBPH-RNAi [Trinity] 73 Adult Viable Adult Viable
LOF1: TBPH-RNAi [Merton] 73 Adult Viable Adult Viable
LOF1: TBPH-RNAi [Maudlin] 126 Death at P Death at P
OE2: hTDP-43WT 72 Adult Viable Death at P
OE1: hTDP-43WT.GFP#10 72 Death at P Death at L3
OE1: hTDP-43WT.GFP#16 72 Death at P Death at L3
OE1: hTDP-43CTF.GFP#14 72 Death prior to L3 N/A
OE1: Flag.hTDP-43WT 73 Death at P Death at L3
OE1: Flag.TBPHWT 73 Death prior to L3 N/A
OE2: TBPHWT 75 Death prior to L3 N/A
OE2: Venus-TBPHWT 75 Death at P Death prior to L3
Hs: FUS; Dm: Caz
LOF: caz1/+* 75 Adult Viable Adult Viable
LOF2: caz-RNAi [Kellogg] 121,127 Adult Viable Adult Viable
LOF2: caz-RNAi [Oriel] N/A Adult Viable Adult Viable
OE2: Flag.cazWT 75 Adult Viable Death at P
OE2: Flag.cazP398L 75 Death at P Death at P
OE2: Flag.hFUSWT 75 Adult Viable Death prior to L3
OE2: HA.hFUSWT 128 Death at P Death at P
OE1: hFUSP525L-RFP.HA 129 Death prior to L3 N/A
OE1: hFUSWT-RFP.HA 129 Death prior to L3 N/A
OE1: hFUSR524S-RFP.HA 129 Death at P Death at P
OE2: Flag.hFUSP525L 75 Death at P Death at L3
Hs: C9orf72
OE2: G4C2-3 123 Adult Viable Adult Viable
OE2: G4C2-36 123 Adult Viable Adult Viable
OE2: GR-36 123 Adult Viable Adult Viable
OE2: GR-100 123 Death prior to L3 N/A
OE2: PR-36 123 Adult Viable Adult Viable
OE2: PR-100 123 Adult Viable Adult Viable
Hs: SOD1; Dm: Sod1
LOF: Sod1n1/+* 80 Adult Viable Adult Viable
LOF2: Sod1-RNAi [Pembroke] 122 Adult Viable Adult Viable
LOF1: Sod1-RNAi [Hertford] 122 Adult Viable Adult Viable
OE1: hSOD1WT 130 Adult Viable Adult Viable
OE2: hSOD1WT. HA 131 Adult Viable Adult Viable
OE1: hSOD1G85R 130 Adult Viable Adult Viable
OE1: hSOD1A4V 130 Adult Viable Adult Viable
OE1: Sod1 130 Adult Viable Adult Viable
Table 1. Alleles of ALS-linked genes investigated in this study and their effect on viability when expressed 
either alone or in combination with Gem3BART in muscle tissue. 1Transgenesis: random insertion; 2Transgenesis: 
Φ-C31 site-specific insertion; *Heterozygote; Hs, Homo sapiens (human); Dm, Drosophila melanogaster (fruit 
fly); N/A = Not Applicable; L3, third instar larval stage; P, pupal stage, LOF, loss of function; OE, overexpression.
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pathophysiology74,77. In this context, we questioned whether upregulation of caz or overexpression of human FUS 
(hFUSWT) can also act as enhancers when placed in a Gem3 mutant background. In this regard, in a wild-type 
background, muscle-restricted increase in Caz protein levels was sufficient to induce both climbing and flight 
defects as early as day 5 post-eclosion (Fig. 3). However, in Gem3BART flies, cazWT upregulation induced lethality 
before eclosion with the majority of flies dying during the pupal stage (Table 1). Similarly, ectopic expression of 
hFUSWT in muscles was enough to cause motor deficits in young adult flies when applied to a wild-type back-
ground (Fig. 3). In combination with Gem3BART, hFUSWT overexpression remarkably induced death during early 
development (Table 1). A trend towards reduced survival was also observed in Gem3BART flies upon expression 
of hFUS with a pathogenic mutation in the C-terminus (hFUSP525L), though not when expressing cazP398L, its 
equivalent in Drosophila (Table 1). Collectively, these findings show that either loss or gain of Caz/FUS function 
aggravate the motor and viability phenotypes of Gem3 mutant flies, which is highly suggestive of a genetic asso-
ciation between Gemin3 and caz/FUS.
expression of C9orf72 repeat expansions has no effect on Gem3 mutant flies. We next sought 
to broaden our investigation by determining whether Gem3 mutant phenotypes are also induced by disruption 
Figure 2. Loss of caz function impacts neuromuscular ability in Gem3 mutant flies. Left panel: In a 
heterozygous caz deficient background, brought about by the caz1 null mutant, Gem3BART flies develop flight 
defects at a late stage during adulthood. Hence, motor deficits become obvious only on day 35 post-eclosion. 
Middle panel: A greater reduction in Caz levels induced by a moderately-expressing RNAi transgene (caz-
RNAi [Kellogg]) induced flight defects at an earlier stage (day 15 post-eclosion) and an increase in severity was 
observed with age. Right panel: A more pronounced age-dependent progressive decline in flight capacity can 
be brought about by knockdown mediated by a stronger RNAi transgene (caz-RNAi [Oriel]). Data presented 
are the mean ± S.E.M. of at least 4 independent experiments, and, for each time point measured, n ≥ 60 per 
genotype. Symbols indicate the sex of the genotype assessed: ♂ = males, and ♀ = females. Significance as tested 
by two-way ANOVA, followed by Bonferroni’s post hoc tests is indicated by the exact p-value.
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of other major ALS-linked genes. C9orf72 is the most frequently mutated gene in ALS. Enormous expansions of 
an intronic hexanucleotide repeat (GGGGCC, G4C2) cause a large portion of familial (25%) and sporadic (10%) 
ALS10. Transcripts containing repeats form intranuclear RNA foci that sequester nuclear proteins. In the cyto-
plasm, expanded RNA also undergoes repeat-associated non-AUG (RAN) translation to produce toxic dipeptide 
repeat (DPR) proteins9. Transgenic expression of a non-pathogenic repeat length (G4C2-3) in muscle tissue had 
no effect on neuromuscular function in either wild-type or Gem3BART flies. Thus, at all time points assessed, flies 
were relatively healthy and no major differences were apparent between the two groups at any stage during their 
adult life (Fig. S2). Although muscle-restricted expression of 36 repeats (G4C2-36), previously shown to be neu-
rotoxic78, caused flight defects in early adulthood, the phenotype in Gem3BART flies was surprisingly identical to 
that of control flies with a wild-type background (Fig. S2). It is noteworthy that a similar outcome was observed 
in either background when assessing animals expressing two arginine-containing DPR proteins, glycine-arginine 
Figure 3. Gain of caz/FUS function in muscle impairs motor performance. (A) Overexpression of either 
caz or human FUS (hFUS) in muscle leads to adult flies with reduced mobility. Hence, on assessment, the 
first fly took significantly longer to reach a pre-set threshold. Furthermore, at a population level, climbing 
success was profoundly reduced. (B) Flies were in their majority non-fliers. Thus, when tested, a significant 
percentage dropped to the base (sector 1) of the Droso-Drome. Importantly, in combination with Gem3BART, 
muscle-specific overexpression of either caz or hFUS induced lethality prior to eclosion. Data presented are the 
mean ± S.E.M. of at least 4 independent experiments, and for each time point measured, n ≥ 60 per genotype. 
Symbols indicate the sex of the genotype assessed: ♂ = males, ♀ = females, and ♀♂ = males + females. Adult-
viable flies were assessed at day 5 post-eclosion. Significance as tested by the unpaired t-test (A) and two-way 
ANOVA, followed by Bonferroni’s post hoc tests (B) is indicated by the exact p-value.
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(GR-36) or proline-arginine (PR-100) (Fig. S2). In addition to confirming that repeats are damaging through 
the production of DPR proteins78, this result underscores that neither expanded repeats nor poly-GR/poly-PR 
proteins enhance Gem3 loss-of-function.
Loss rather than gain of Sod1 function enhances motor deficits in Gem3 mutant flies. The 
first ALS gene to be identified was SOD1, which encodes for the Cu-Zn superoxide dismutase, an abundant 
ubiquitously-expressed cytoplasmic enzyme. SOD1 is the second most commonly mutated gene in ALS, con-
tributing to 20% and 2% of familial and sporadic cases, respectively10. SOD1 performs an important antioxidant 
function by catalysing the conversion of highly reactive superoxide to hydrogen peroxide or oxygen. Nevertheless, 
neuromuscular degeneration is thought to be driven by one or more acquired toxicities of the mutant protein 
rather than loss of dismutase activity. Indeed, similar to TDP-43 and FUS, most ALS-causing SOD1 mutants 
form ubiquitinated cytoplasmic aggregates that are toxic to various cellular processes79. Against this backdrop, 
we investigated whether gain of Sod1 function is also capable of triggering motor dysfunction in Gem3 mutant 
flies. We found that neither overexpression of Drosophila Sod1 nor ectopic expression of wild-type human SOD1 
(hSOD1WT) had any negative effect in either a wild-type or a Gem3 mutant background (Fig. 4). Expression 
of pathogenic variants including hSOD1A4V or hSOD1G85R gave a similar result, hence they were not damag-
ing in either genetic background (Fig. 4). Interestingly, we were surprised to note that less than 50% reduction 
in enzymatic activity, brought about by heterozygosity for the missense allele Sod1G51S (+/Sod1G51S)80, induced 
a prominent decrease in neuromuscular function during late adulthood in Gem3 mutant flies, suggesting that 
these organisms are susceptible to oxidative stress when they get old. We confirmed this result through the use 
of muscle-specific RNAi-mediated loss of Sod1 function in wild-type versus Gem3BART flies. Hence, we show 
that an RNAi transgene targeting the C-terminus (Sod1-RNAi [Pembroke], Supplementary Fig. S1) similarly pro-
voked flight defects in adult flies aged to day 35 post-eclosion (Fig. 5). Motor defects became apparent at an 
even earlier stage (day 25 post-eclosion) when we made use of a stronger RNAi transgene targeting the same 
region but having a longer hairpin sequence (Sod1-RNAi [Hertford], Fig. 5 and Supplementary Fig. S1). Overall, 
these findings demonstrate that Gem3 mutant phenotypes are hastened by Sod1 loss-of-function rather than by 
gain-of-function, hence allowing us to uncover a genetic interaction between Gemin3 and Sod1.
TDP-43 or FUS gain of function enhance muscle atrophy and suppresses neuromuscular junction 
overgrowth in Gem3 mutant flies. Above we showed that upregulation of caz or TBPH, in flies with Gem3 
loss of function, induced adult lethality. Overexpression of the respective human homologue gave an analogous 
outcome. We next investigated whether the neuromuscular function of these animals is perturbed prior to their 
death. Gem3BART animals devoid of any genetic modifying factor(s) eclose normally and neuromuscular function 
is relatively unperturbed in adult flies. Surprisingly, when analysing larval crawling, we observed a slight yet 
significant decline in mobility in Gem3BART larvae compared to their wild-type counterparts (Fig. 6A). Notably, 
this difference can be explained by a substantial difference in muscle surface area between Gem3 mutant and 
control larvae. Thus, the former had a pronounced reduction in muscle size (Fig. 6B). We asked whether these 
phenotypes are amenable to modification by genetic factors. To this end, we introduced Gaulos RNAi in Gem3 
mutants. Gaulos (Glos) was recently identified as the Drosophila orthologue of Gemin467,81, a putative co-factor 
of Gemin382. Remarkably, muscle-driven Glos reduction caused a further decline in both the locomotor ability 
(Fig. 6A) and muscle size of Gem3BART larvae (Fig. 6B), hence confirming that the phenotypes can be genetically 
enhanced. Importantly, we demonstrate that compared to the baseline provided by Gem3BART larvae, ectopic 
expression of either hTDP-43 or hFUS was responsible for an additional degree of sluggishness in larvae as 
demonstrated by their less frequent movements (Fig. 6A). Interestingly, the difference was reflected in muscle 
size, hence muscle atrophy was greatly enhanced upon TDP-43 or FUS gain-of-function (Fig. 6B). Upregulation 
of TBPH causes Gem3BART flies to die before the third instar larval stage (Table 1), hence precluding assessment 
of flies. Upregulation of caz in Gem3BART flies induces larval mobility defects but has no effect on muscle size 
(data not shown). However, overexpression of the pathogenic variant cazP398L in Gem3BART flies was found to mir-
ror the neuromuscular phenotypes observed on TDP-43/FUS gain of function in the same genetic background 
(Fig. 6A,B).
Consequent to muscle atrophy and the subsequent decline in muscle power, all genotypes assessed failed 
to contract adequately during pupariation. Hence, in a Gem3BART genetic background, Glos knockdown (serv-
ing as a positive control) or overexpression of hTDP-43/hFUS/cazP398L, all induced a puparial axial ratio that 
was significantly higher than the baseline observed in Gem3 mutant flies devoid of any genetic manipulation 
(Fig. 6C). Finally, we assessed the morphology of the neuromuscular junction (NMJ). Muscle-directed expres-
sion of Gem3BART causes an appreciative expansion of the NMJ (Fig. 7A), hence, parameters including area 
(Fig. 7B), number of branches (Fig. 7C) and bouton numbers (Fig. 7D) were all significantly elevated compared 
to the wild-type control. This phenotype was similar to that previously reported for flies with homozygous Gem3 
loss-of-function in all tissues65. NMJ overgrowth was also observed on Glos knockdown and upon expression of 
cazP398L, both of them directed to muscle (Fig. 7). No deviations from the wild-type NMJ parameters were how-
ever seen on expression of either hTDP-43 or hFUS in muscle (Fig. 7). Interestingly, in a Gem3BART background, 
expression of hTDP-43, hFUS and, to a slightly lower degree, cazP398L (but not Glos RNAi) suppresses the NMJ 
overgrowth phenotype associated with Gem3 loss-of-function, with key NMJ morphology parameters reduced 
to the wild-type range (Fig. 7). In sum, these observations strengthen the evidence favouring the possibility that 
Gemin3 acts together with TBPH/TDP-43 and caz/FUS within a genetic pathway that influences viability and 
neuromuscular function.
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Self-association of full-length Gemin3 explains loss of function induced by the Gem3BARt 
mutant. In conclusion, we wished to gain insights into the mode of action of the Gem3BART allele, a hypo-
morphic or weaker version of the Gem3ΔN mutant. The latter differs from wild-type Gemin3 in that it lacks the 
N-terminus which hosts the helicase domains68. Previously, we have shown that expression of Gem3ΔN mimics 
Gem3 knockdown and, together, the genetic alterations cause lethality. This allowed us to conclude that expres-
sion of Gem3ΔN in a wild-type background induces a loss of Gemin3 function64. We hypothesised that Gem3ΔN 
interacts with its wild-type full-length counterpart and in so doing, it interferes with its function. This model 
assumes that Gemin3 is capable of self-association for which the evidence is presently lacking. Through a yeast 
two-hybrid assay, we confirm this model, hence, we show that Drosophila Gemin3 is able to strongly interact with 
itself (Fig. 8A). Although this property is lost with Gem3ΔN, remarkably, we demonstrate that Gem3ΔN is capable 
of binding to its full-length counterpart (Fig. 8A).
We next questioned whether the Gem3ΔN-Gem3 interaction is stronger than the one between wild-type 
Gemin3 monomers, hence favouring the capture of endogenous Gemin3 into non-functional oligomers. To 
this end, we re-performed the yeast two-hybrid assay in the presence of 3-amino-1,2,4-triazole (3-AT). 3-AT 
Figure 4. Sod1 gain-of-function has no effect on motor behaviour in Gem3 mutant flies. Overexpression of 
either Sod1 or human SOD1 (hSOD1) is not deleterious to animals with a marginal loss of Gem3 function (left 
panel). Overexpression of pathogenic hSOD1 A4V or G85R variants is equally not a damaging factor to Gem3 
mutant flies (right panel). Organisms did not show differences in motor function at all time points assessed. 
Data presented are the mean ± S.E.M. of at least 4 independent experiments, and, for each time point measured, 
n ≥ 60 males (♂) per genotype.
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competitively inhibits imidazole glycerol-phosphate dehydratase, a histidine (His) biosynthetic enzyme, thus 
limiting His synthesis83,84. We demonstrate that yeast containing both the Gem3 bait and the Gem3ΔN prey were 
capable of growing on –Leu–Trp–His selective plates at 20 mM 3-AT (Fig. 8B), thus indicating that the two-hybrid 
Gem3-Gem3ΔN interaction is strong enough to overcome the growth inhibitory effect of 3-AT in the medium. 
In summation, these findings are first supportive of Gemin3 self-binding. Second, they allow us to postulate that 
the dominant-negative nature of Gem3ΔN arises from its most-favourable binding to endogenous Gemin3. This is 
predicted to titre wild-type Gemin3 into non-functional dimers or oligomers.
Discussion
In this study, we sought to determine whether a functional interaction exists between Gemin3, a core SMN com-
plex component, and major ALS-associated proteins. Focusing on motor behaviour, muscle mass, NMJ structure 
and survival, which are all profoundly affected in motor neuron disease, we show that disruption of either TBPH/
TDP-43 or Caz/FUS enhance muscle defects but are able to suppress NMJ morphology deficits, both induced 
by Gemin3 loss-of-function. We also found that depletion of Sod1 has an enhancing effect on neuromuscular 
function in old age. In addition to highlighting shared pathways most likely involving aspects of ribostasis and 
oxidative stress, our findings reinforce the link between SMA and ALS. Importantly, they extend our knowledge 
on the function of Gemin3, showing for the first time that it self-interacts, which is a property that makes it prone 
to loss of function.
Figure 5. Loss of Sod1 function impairs motor behaviour in Gem3 mutant flies. Placed in a Gem3BART genetic 
background, heterozygotes for an enzymatic null Sod1 allele (+/Sod1G51S) only induce deficits in old age (left 
panel). A similar outcome is achieved in Gem3BART flies with muscle-selective RNAi-mediated knockdown of 
Sod1 (middle panel). The use of a stronger RNAi transgene causes defects at an earlier stage of adult life (right 
panel). Data presented are the mean ± S.E.M. of at least 4 independent experiments, and, for each time point 
measured, n ≥ 60 males (♂) per genotype. Significance as tested by two-way ANOVA, followed by Bonferroni’s 
post hoc tests, is indicated by the exact p-value.
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Defective chaperoning of spliceosome assembly and/or missplicing have long been known to have a major 
role in the pathophysiology of motor neuron degeneration. A plethora of in vivo studies unequivocally show that 
snRNP assembly defects and the consequential missplicing events can induce the selective motor phenotype that 
is typical in SMA patients (reviewed in ref. 6). In this regard, we have recently shown that, in Drosophila, pertur-
bation of snRNP biogenesis factors pICln or Tgs1 causes motor deficits that mirror those brought about by loss 
of SMN or select Gemins including Gemin361. This corroborates earlier findings demonstrating that knockdown 
of pICln or U1 snRNP leads to MND-like phenotypes in zebrafish85,86. Notably, by discovering an interaction 
between Gemin3 and either pICln or Tgs161, we underscored that these factors participate in a common pathway 
that most likely centres on the synthesis of snRNPs which form the backbone of the spliceosome. Here, we widen 
our findings by uncovering a genetic association between Gemin3 and two RBPs with important roles in diverse 
Figure 6. Overexpression of hTDP-43 or hFUS/cazP398L in Gem3 mutant flies causes early mobility defects, 
reduced muscle size and aberrant puparial structures. (A) Third instar larvae with muscle-specific Gem3BART 
expression have a significant reduction in velocity compared to wild-type controls. This deficit was profoundly 
enhanced on overexpression of hTDP-43WT, hFUSWT or cazP398L. A similar result was obtained on knockdown 
of Gaulos (Glos RNAi), which served as a positive control. In the absence of Gem3BART, only overexpression 
of hTDP-43WT or hFUSWT was found to induce a decrease in larval mobility compared to wild-type animals. 
(B) Compared to the wild-type control, Gem3BART larvae also show a significant reduction in muscle size 
that dramatically worsens on Glos knockdown or upon overexpression of hTDP-43WT, hFUSWT, or cazP398L, 
all directed to muscle. In a wild-type background, muscle size was also found reduced in larvae with Glos 
knockdown or those overexpressing FUS/cazP398L. (C) Sluggish larval behaviour leads to the formation of 
puparia that have a significantly higher axial ratio (defined as length/width) compared to the baseline offered 
by Gem3BART larvae. In (A–C) data presented are the mean ± S.E.M. of at least 3 independent experiments, and 
n ≥ 15 per genotype. Equal number of male and female larvae were used in each assay. Significance as tested by 
the unpaired t-test is indicated by the exact p-value, shown either in blue (comparison to wild-type larvae) or 
black (comparison to Gem3BART larvae).
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Figure 7. Overexpression of hTDP-43 or hFUS/cazP398L suppresses NMJ expansion in Gem3 mutant flies. 
(A) Representative images of NMJs innervating ventral longitudinal muscles 6 and 7 in third instar larvae 
stained with post-synaptic anti-DLG antibody (scale bar = 10 μm). Visual inspection reveals that compared to 
wild-type, muscle-directed expression of Gem3BART induces an overgrown NMJ morphology that is restored 
on overexpression of hTDP-43WT, hFUSWT and, to a lesser degree, cazP398L. An overgrowth phenotype is also 
obvious on Glos knockdown (applied singularly or combined with Gem3BART) or in flies expressing cazP398L. 
These observations were confirmed upon quantification of NMJ area (B), number of branches per NMJ (C) and 
number of boutons within a single NMJ (D). In (B–D) data presented are the mean ± S.E.M. and n ≥ 18 per 
genotype. Equal number of male and female larvae were assessed. Significance as tested by the unpaired t-test is 
indicated by the exact p-value, shown either in blue (comparison to wild-type larvae) or black (comparison to 
Gem3BART larvae).
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Figure 8. Full-length Gemin3 interacts not only with itself but also with Gem3ΔN. (A) Measurement of 
β-galactosidase activity was used to assay the expression of the GAL1-LacZ reporter gene that is produced 
by the combinations of the indicated proteins. Full-length Gemin3 interacts with itself or with its N-terminal 
truncated form (Gem3ΔN). Gem3ΔN is not capable of self-binding. An empty vector served as a negative control. 
Individual bars represent the mean ± S.E.M. β-galactosidase activity of 3 independent experiments. Significance 
as tested by one-way ANOVA is indicated by the exact p-value. (B) The reporter strain carrying yeast two-
hybrid plasmids expressing the indicated proteins was spotted in serial dilutions on –Leu–Trp–His plates in 
the presence of 20 mM 3-AT. Under these conditions, Gem3-Gem3 interaction is unfavourable whereas the 
Gem3-Gem3ΔN association remains favourable. Interaction between Gem3 or Gem3ΔN with Gemin2 served as 
a negative control. At least 3 independent experiments were performed, and the result of one representative is 
shown. (C) Model for Gemin3 dimerisation. Left, Gemin3 monomers are hypothesised to bind to each other in 
the reverse direction. Middle, The Gem3ΔN mutant is a truncated version of Gemin3 lacking the N-terminus, 
which hosts the helicase domains. In the presence of Gem3ΔN, wild-type:mutant dimers are favoured more 
than wild-type:wild-type dimers. Right, A model predicting self-association in the opposite orientation infers 
that Gem3ΔN is not self-binding, hence, mutant:mutant dimers do not form. Abbreviations: N, N-terminus; C, 
C-terminus.
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aspects of RNA metabolism, namely TDP-43 and FUS. Our data suggest that Gemin3, TDP-43 and FUS function 
in overlapping pathways that influence viability, muscle mass, NMJ morphology and motoric ability.
Considering the roles of Gemin3, TDP-43 and FUS at different points in the life of the spliceosome, we spec-
ulate that the intersecting pathways are vital for the correct splicing of mRNAs, which we believe is a main con-
tributor to the health and optimal function of the neuromuscular system. In support, although its exact activities 
in snRNP assembly remain unclear, Gemin3 is indispensable for this process in vivo60. Considering TDP-43 
and FUS, long before their implication in ALS, these two proteins were reported to influence pre-mRNA splic-
ing or interact with known splicing factors87,88. Both RBPs were later shown to bind to predominantly UG-rich 
sequences in RNA transcripts, regulating the expression and alternative splicing of multiple yet distinct target 
genes, particularly those with exceptionally long introns89–93. Thus, loss of TDP-43 or FUS in cell lines or mouse 
brain leads to splicing defects that are mostly different for either factor89,90,92,94,95. Even splicing of snRNP compo-
nents is altered based on studies in sporadic ALS patient-derived lower motor neurons that had nuclear TDP-43 
depletion96 or FUS knockdown in a human cell line97. Overexpression of ALS-causing TDP-43 or FUS mutants, 
which cause neuromuscular phenotypes in mice, were also found to induce aberrant RNA splicing98,99. Similarly, 
Drosophila with knockout or overexpression of TBPH exhibit splicing alterations100. Interestingly, expression 
levels of several snRNAs were found significantly increased in brains of flies overexpressing human TDP-43101 
and decreased in fibroblasts derived from ALS patients with FUS mutations or FUS transgenic mice19. Notably, in 
an ALS mouse model, an endogenous C-terminal domain mutation in TDP-43 was recently reported to induce 
a gain of splicing function. Hence, splicing activity of TDP-43 was modified in such a way that it leads to the 
excision of otherwise normally conserved exons, thereby, termed ‘skiptic exons’102. Pathogenic TDP-43 or FUS 
mutations are also known to affect splicing in a gain-of-toxic-function manner by mislocalising snRNPs, SMN 
and splicing factors (PSF and NeuN) to the cytosol18,19,86,103,104.
It is interesting to note that whereas gain of TDP-43 or FUS function were both shown to enhance Gemin3 
motor deficits, we observed that loss-of-function was consequential only for FUS. This can be explained by the 
more intimate relationship of FUS with the SMN complex. In this respect, in addition to U1 (and U11) snRNP 
components19,103, SMN complex members including SMN and Gemin3 were shown to be integral members of 
the FUS interactome19. It is plausible that the SMN complex might collaborate with FUS in an as yet unknown 
snRNP-related function, which is disrupted by deviations from normal Caz/FUS levels. Thus, ALS-causative 
mutations in FUS were found to strengthen the interaction with SMN potentially sequestering SMN and, most 
probably, its associates, from their normal localisation and function19. It is important to note that we do not 
exclude the possibility that Gemin3 cooperates with TDP-43 and FUS in other steps of RNA metabolism including 
transcription or RNA transport given that all three factors are known to participate in either process11,12,28,60,105.
Gem3 mutant phenotypes were not hastened by SOD1 or C9orf72 gain-of-function. This allows us to infer that 
the genetic interaction between Gemin3 and TBPH/TDP-43 or caz/FUS is specific. Nonetheless, reduced levels of 
Sod1 brought about by heterozygosity for a Sod1 mutant or RNAi-mediated knockdown were surprisingly found 
to induce motor deficits in Gem3 mutant flies during late adulthood. Oxidative stress is exacerbated by age106 
and paucity of Sod1107–109. Notably, snRNP assembly function of the SMN complex was found to be inhibited by 
oxidative stress in a dose-dependent manner110. This observation adds to the plethora of evidence showing that 
oxidative stress perturbs RNA metabolism (reviewed in ref. 111). Thus, it is reasonable to speculate that oxidative 
stress is a modifying factor for Gemin3 function in snRNP synthesis as part of the SMN complex.
Ectopic overexpression of the helicase core deletion mutant Gem3ΔN in a wild-type background induces 
phenotypes that overlap those resulting from Gemin3 loss-of-function. In this regard, either overexpression of 
Gem3ΔN or RNAi-mediated knockdown of Gemin3, both targeted to muscle tissue, was shown previously to dis-
rupt motor behaviour. Applied simultaneously, these two genetic manipulations were found to cause lethality64. 
Thus, the evidence favours the possibility that Gem3ΔN interferes with endogenous Gemin3 to induce loss of func-
tion, hence acting as a dominant-negative mutant or a Muller’s antimorph. Here, we show that Gemin3 is capable 
of self-interaction and Gem3ΔN retains the ability to interact with its wild-type counterpart. Importantly, analysis 
of interaction strength demonstrates that wild-type:mutant dimers are favoured more than wild-type:wild-type 
dimers (Fig. 8C). Based on these findings, we predict that Gem3ΔN titres endogenous Gemin3 into non-functional 
dimers or oligomers. Sequestration of Gemin3 can perturb SMN complex stoichiometry in addition to inhibiting 
the participation of Gemin3 in SMN complex-related activities including snRNP assembly or recycling.
The formation of wild-type:mutant dimers or even oligomers can potentially hinder the catalytic activity of 
Gemin3, thus raising the question of whether dimerization of Gemin3 is a prerequisite for its ATPase-dependent 
RNP chaperoning activities. Self-interaction that is independent of the RNA substrate is rather unusual for mem-
bers of the DEAD-box RNA helicase family. It has been reported in prokaryotes for Escherichia coli RhIB112, 
Thermus thermophilus Hera113, Bacillus subtilis CshA114 and cyanobacteria CrhR115. In this context, our findings 
add Gemin3 to the growing list of eukaryotic DEAD-box RNA helicases that also have a self-interaction property 
including transcriptional regulators DDX5/p68 and DDX17/p72116. Domain analysis of both T. thermophilus 
Hera and B. Subtilis CshA revealed that efficient dimerization is dependent on protein regions other than the 
those hosting the two highly-conserved RecA-like helicase domains which are required for RNA substrate bind-
ing and catalytic activity113,114. For E. coli RhIB, cyanobacteria CrhR115 and eukaryotic DDX5 or DDX17, a large 
part of the conserved core was required for self-association112,116, a finding that also applies for Gemin3. To this 
end, we show that, alone, the C-terminal domain of Gemin3 is incapable of self-binding, hence, the formation of 
Gem3ΔN homodimers is an unfavourable reaction (Fig. 8C). However, interaction is observed in the presence of 
the N-terminus, making the formation of Gem3ΔN:Gem3 dimers a highly favourable reaction. This indicates that 
self-interaction requires that the full-length protein is present in at least one of the two monomers, thus raising 
the possibility that Gemin3 monomers bind to each other in the reverse direction. This model warrants future 
investigation through further molecular and structural studies.
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Given the functional interaction of ALS-linked TBPH/TDP-43, Caz/FUS and Sod1 with Gemin3, which itself 
is intimately associated with the SMA-causative SMN, our work adds to the substantial collection of evidence 
supporting convergence of the molecular mechanisms of two major MNDs. Although we speculate that defects 
in RNA metabolism might be central to the pathophysiology of ALS and SMA, further investigation of the mech-
anistic overlaps is now possible in a genetically-tractable model organism. Importantly, given our findings, we 
propose Gemin3 as a candidate for modifying motor neuron degeneration.
Materials and Methods
Flies. Flies were cultured on food consisting of sugar, corn meal, yeast, and agar in plastic vials at an incubation 
temperature of 25 °C under 12 hours day/night cycles. The wild-type strain was w1118. For adult-based assays, male 
flies were used except where indicated. In instances where females were used, flies were virgins. For larval-based 
assays, equal number of male and female larvae were assessed. Inducible transgenes were expressed via the bipar-
tite GAL4/upstream activation sequence (UAS) system (reviewed in ref. 117). Muscle-exclusive expression was 
achieved through the use of the Mef2-GAL4 driver118. The Gem3BART allele (UAS.Gem3BART) was generated previ-
ously by transposition of the Gem3ΔN transgenic allele into a repressive region on chromosome 268. The UAS.Glos-
IRDEX (Glos RNAi) transgene was described and characterised previously67. TBPHΔ23 and caz1 are small deletions 
that partially remove the coding and 5’ sequence of TBPH73 and caz75, respectively. They are considered as null 
alleles of the respective gene. The Sod1G51S mutant (also known as Sod1n108 or Sod1n1) carries an EMS-generated 
missense mutation in the Sod1 gene that disrupts dimer contact119. Sod1G51S homozygotes were reported to be 
null for superoxide dismutase activity. In Sod1G51S heterozygotes, superoxide dismutase activity was reported to 
be close to 40%80. The RNAi transgenic constructs, UAS.TBPH-RNAi [Trinity] (ID: 38377), UAS.TBPH-RNAi 
[Merton] (ID: 38379), UAS.TBPH-RNAi [Maudlin] (ID: 104401), UAS.caz-RNAi [Kellogg] (ID: 100291), UAS.caz-
RNAi [Oriel] (ID: 330388), UAS.Sod1-RNAi [Hertford] (ID: 31551), and UAS.Sod1-RNAi [Pembroke] (ID: 108307) 
were obtained from the Vienna Drosophila Resource Center, Austria120, and were described previously73,121,122. 
The provenance of the various UAS transgenes for TBPH, hTDP-43, caz, hFUS, Sod1 and hSOD1 is referenced 
in Table 1. All C9orf72-related transgenic lines were obtained from the Bloomington Drosophila Stock Center 
(NIH P40OD018537) at Indiana University, USA and were characterised previously123. Combination of the var-
ious genetic tools including GAL4 drivers, alleles, and transgenes was performed according to standard genetic 
crossing schemes.
Mobility assays. Mobility assays in larvae and adult flies were conducted as described previously67. In brief, 
third instar larvae were first placed on a 0.7% agar plate. Subsequently, the number of forward body wall contrac-
tions exhibited by the organism in 30 seconds were counted. Each larva was assessed three times before an average 
was taken. To assess climbing performance in adult flies, two empty polystyrene tubes were vertically joined by 
tape facing each other. Flies (15–20) were then transferred into the lower tube and allowed to acclimatize. Flies 
were then gently tapped down to the bottom of the vial. The time for the first fly within a group to cross an 8 cm 
threshold was first measured. Consequently, the number of flies per group, that can climb above the 8 cm mark 
by 10 seconds, was determined. For each group of flies, four trials were performed. A minimum of four groups 
were assayed per genotype.
Flight assay. Flight performance was assessed as detailed previously61,67. This assay made use of the 
Droso-Drome apparatus, which consists of a 1 L glass bottle coated with an alcohol-based sticky fluid, and divided 
into 4 sectors, of 5 cm each, spanning a total height of 20 cm. In short, flies first underwent a ‘warm-up’ by induc-
ing negative geotaxis in an empty tube for 6 times. Organisms were then dropped into the Droso-Drome to 
induce flight. The number of flies stuck to each sector was next counted, divided by the total number of flies 
dropped and multiplied by 100 to generate the percentage number of flies per sector. Fight ability correlates with 
the height or sector in which flies are distributed, hence, fly percentages that are skewed towards the lower sectors 
of the Droso-Drome are indicative of reduced flight capacity.
Puparial axial ratios. Length and width of puparia were first measured from still images. As reported previ-
ously61,67, calculation of puparial axial ratios involved dividing the length by the width of the puparia.
Immunohistochemistry. The same immunohistochemistry procedures described previously65 were fol-
lowed. Briefly, body wall muscles of wandering third instar larvae were dissected in phosphate buffered saline 
(PBS), fixed in 4% paraformaldehyde in PBS and washed in PBS + 0.1% Triton X-100 (PBT). Tissues were then 
stained overnight at room temperature by mouse anti-Discs large antibody (1:1000; Developmental Studies 
Hybridoma Bank, University of Iowa, USA). On the following day, tissues were washed in PBT and stained over-
night at room temperature with anti-mouse Alexa Fluor 488-conjugated secondary goat antibody (1:50) and 
Alexa Fluor 546-conjugated Phalloidin (1:50). After a final wash in PBT, the samples were mounted in 90% glyc-
erol with anti-fade. Imaging was performed with Optika B-600TiFL microscope (20x or 40x objectives).
Analysis of muscle size and NMJ morphology. ImageJ software (NIH) was used to quantify both mus-
cle and NMJ area. The former comprised of both ventral longitudinal muscles 6 and 7 derived from abdominal 
segments 2–4 whereas the latter constituted the postsynaptic region on the same muscles stained by the anti-Discs 
large antibody. Branch number was determined by counting the number of arborisations containing at least two 
boutons within a single NMJ. To determine, bouton numbers, all boutons were counted within a single NMJ.
Yeast two-hybrid assays. Two-hybrid assays were performed as described previously67. Briefly, baits and 
preys were obtained by PCR amplification of cDNA and ligation into the pAS∆∆ and pACT2st vectors, respec-
tively124. Primer sequences and PCR regimes are available upon request. The cDNA clones for Gemin2 (LD47479) 
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and Gemin3 (LD05563) were obtained from the Drosophila Genomics Resource Centre (Indiana University, 
USA). Gem3ΔN was synthesised as described previously65. The bait pAS∆∆ construct containing the protein 
sequence fused in frame with the GAL4 DNA binding domain (GAL4-BD) was used to transform the CG1945 
strain, which was then selected on –Trp plates. The prey pACT2st construct containing the protein sequence 
fused in frame with the GAL4 activation domain (GAL4-AD) was used to transform the Y187 strain, which was 
then selected on –Leu plates. Mating of bait and prey strains was achieved overnight on rich yeast extract pep-
tone dextrose (YPD) plates and –Trp –Leu plates were used to select diploids containing bait/prey combinations. 
Protein-protein interactions were screened by spotting serial dilutions on –Trp–Leu–His plates. Where indicated, 
30 mM 3-amino-1,2,4-triazole (3-AT) was added to the medium to assess interaction strength. Incubations were 
performed at 28° C for 3 to 5 days. The β-galactosidase assay was used to quantify yeast two-hybrid interactions. 
Cells were grown in –Trp–Leu selective medium to an OD600 = 0.5–1.0. Activity was measured from extracts as 
reported previously125.
Statistical analysis. Values are presented as means ± S.E.M. unless otherwise indicated. The unpaired t-test 
was used to compare measures between 2 groups whereas one-way ANOVA was applied for multiple comparisons 
with the control. Two-way ANOVA, followed by Bonferroni’s post hoc test, was used to determine differences 
between 2 groups in the percentage number of fliers (sectors 2–4) vs. non-fliers (sector 1) in the flight assay 
(GraphPad Prism v8.0.1). Differences were deemed statistically significant if p < 0.05, and when this is the case, 
the exact p-value is presented.
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